WINTON GROUP Ltd Has $5.45 Million Holdings in Dynavax Technologies Co. (NASDAQ:DVAX)

WINTON GROUP Ltd lifted its stake in shares of Dynavax Technologies Co. (NASDAQ:DVAX) by 339.0% during the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 426,814 shares of the biopharmaceutical company’s stock after purchasing an additional 329,579 shares during the period. WINTON GROUP Ltd owned approximately 0.32% of Dynavax Technologies worth $5,450,000 at the end of the most recent reporting period.

Other hedge funds have also modified their holdings of the company. PDT Partners LLC acquired a new position in Dynavax Technologies during the 3rd quarter worth $3,967,000. Nordea Investment Management AB lifted its stake in shares of Dynavax Technologies by 42.7% during the fourth quarter. Nordea Investment Management AB now owns 777,816 shares of the biopharmaceutical company’s stock valued at $10,034,000 after acquiring an additional 232,690 shares during the period. Barclays PLC boosted its holdings in Dynavax Technologies by 137.4% in the third quarter. Barclays PLC now owns 302,572 shares of the biopharmaceutical company’s stock valued at $3,371,000 after acquiring an additional 175,118 shares during the last quarter. Bank of Montreal Can increased its position in Dynavax Technologies by 8.3% in the third quarter. Bank of Montreal Can now owns 1,077,081 shares of the biopharmaceutical company’s stock worth $11,848,000 after purchasing an additional 82,449 shares during the period. Finally, SG Americas Securities LLC bought a new stake in Dynavax Technologies during the 4th quarter worth about $990,000. 96.96% of the stock is owned by institutional investors.

Dynavax Technologies Stock Down 2.9 %

Shares of NASDAQ:DVAX opened at $13.58 on Thursday. The company has a 50 day moving average price of $13.29 and a two-hundred day moving average price of $12.46. The company has a debt-to-equity ratio of 0.33, a quick ratio of 12.34 and a current ratio of 13.23. The company has a market capitalization of $1.68 billion, a PE ratio of 75.44 and a beta of 1.23. Dynavax Technologies Co. has a 52 week low of $9.74 and a 52 week high of $14.63.

Dynavax Technologies (NASDAQ:DVAX) last released its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported $0.05 EPS for the quarter, meeting analysts’ consensus estimates of $0.05. The business had revenue of $72.03 million during the quarter, compared to analysts’ expectations of $72.70 million. Dynavax Technologies had a net margin of 9.85% and a return on equity of 4.22%. Analysts forecast that Dynavax Technologies Co. will post 0.32 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently commented on DVAX. StockNews.com upgraded shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research report on Monday, February 24th. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a research report on Friday, February 21st. The Goldman Sachs Group cut Dynavax Technologies from a “neutral” rating to a “sell” rating and decreased their price objective for the stock from $15.00 to $12.00 in a research note on Tuesday, February 11th. Finally, HC Wainwright reiterated a “buy” rating and issued a $31.00 price objective on shares of Dynavax Technologies in a report on Friday, February 21st.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.